Evidence map›Paper›PMID 25962410›Full record

Trial reportEuropean journal of neurology2015

A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients.

P Barone, G Santangelo, L Morgante, M Onofrj, G Meco, G Abbruzzese, U Bonuccelli, G Cossu, G Pezzoli, P Stanzione and 3 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 7 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 7 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Trazodone for management of depression in Parkinson's disease: expert opinion and proposal for a treatment algorithm.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 1 country.

P BaroneUniversity of Salerno, Baronissi, Italy.
G SantangeloSecond University of Naples, Caserta, Italy.
L MorganteUniversity of Messina, Messina, Italy.
M OnofrjUniversity of Chieti-Pescara, Chieti, Italy.
G Meco'Sapienza' University of Rome, Rome, Italy.
G AbbruzzeseUniversity of Genoa, Genoa, Italy.
U BonuccelliUniversity of Pisa, Pisa, Italy.
G CossuAO Brotzu, Cagliari, Italy.
G PezzoliParkinson Institute, Milan, Italy.
P StanzioneIRCCS Fondazione S Lucia, Rome, Italy.
L LopianoUniversity of Torino, Torino, Italy.
A AntoniniIRCCS Ospedale San Camillo, Venice, Italy.
M TinazziUniversity of Verona, Verona, Italy.
Azienda Ospedaliera G. Brotzu · ITIRCCS San Camillo Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITSapienza University of Rome · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Chieti-Pescara · ITUniversity of Genoa · ITUniversity of Messina · ITUniversity of Pisa · ITUniversity of Salerno · ITUniversity of Turin · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeDepressed mood is a common psychiatric problem associated with Parkinson's disease (PD), and studies have suggested a benefit of rasagiline treatment.

methodsACCORDO (see the ) was a 12-week, double-blind, placebo-controlled trial to evaluate the effects of rasagiline 1 mg/day on depressive symptoms and cognition in non-demented PD patients with depressive symptoms. The primary efficacy variable was the change from baseline to week 12 in depressive symptoms measured by the Beck Depression Inventory (BDI-IA) total score. Secondary outcomes included change from baseline to week 12 in cognitive function as assessed by a comprehensive neuropsychological battery; Parkinson's disease quality of life questionnaire (PDQ-39) scores; Apathy Scale scores; and Unified Parkinson's Disease Rating Scale (UPDRS) subscores.

resultsOne hundred and twenty-three patients were randomized. At week 12 there was no significant difference between groups for the reduction in total BDI-IA score (primary efficacy variable). However, analysis at week 4 did show a significant difference in favour of rasagiline (marginal means difference ± SE: rasagiline -5.46 ± 0.73 vs. placebo -3.22 ± 0.67; P = 0.026). There were no significant differences between groups on any cognitive test. Rasagiline significantly improved UPDRS Parts I (P = 0.03) and II (P = 0.003) scores versus placebo at week 12. Post hoc analyses showed the statistical superiority of rasagiline versus placebo in the UPDRS Part I depression item (P = 0.04) and PDQ-39 mobility (P = 0.007) and cognition domains (P = 0.026).

conclusionsTreatment with rasagiline did not have significant effects versus placebo on depressive symptoms or cognition in PD patients with moderate depressive symptoms. Although limited by lack of correction for multiple comparisons, post hoc analyses signalled some improvement in patient-rated cognitive and depression outcomes.

Indexed as

AgedDepressionDouble-Blind MethodFemaleHumansIndansMaleMiddle AgedNeuroprotective AgentsParkinson DiseaseTreatment OutcomeIndansNeuroprotective AgentsrasagilinecognitiondepressionParkinson's diseaserasagiline

Identifiers

PMID25962410
PMCPMC4676931
OpenAlexW1728922767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.